Efficacy of MND-2119 in Participants With Hypertriglyceridemia

NCT03693131 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

580

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertriglyceridemia

Interventions

DRUG: Icosapent (MND-2119)
DRUG: Icosapent (EPADEL CAPSULES 300)

Sponsor

Mochida Pharmaceutical Company, Ltd.